Immune Biomarkers in Metastatic Castration-resistant Prostate Cancer

Background: Metastatic castration-resistant prostate cancer (mCRPC) is a heterogeneous disease in which molecular stratification is needed to improve clinical outcomes. The identification of predictive biomarkers can have a major impact on the care of these patients, but the availability of metastatic tissue samples for research in this setting is limited. Objective: To study the prevalence of immune biomarkers of potential clinical utility to immunotherapy in mCRPC by tumour RNA sequencing, and to determine their association with overall survival (OS).

Type: RNASeq
Archiver: European Genome-Phenome Archive (EGA)

1 Dataset 2 Publications

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID	Description	Technology	Samples
EGAD50000001811	RNA sequencing of mCRPC patient biopsies obtained for the profiling of the prevalence of immune transcripts. Manuscript can be found at PMID: 35491356	NextSeq 500	95

Publications	Citations
Immune Biomarkers in Metastatic Castration-resistant Prostate Cancer. Fenor de la Maza MD, Chandran K, Rekowski J, Shui IM, Gurel B, Cross E, Carreira S, Yuan W, Westaby D, Miranda S, Ferreira A, Seed G, Crespo M, Figueiredo I, Bertan C, Gil V, Riisnaes R, Sharp A, Rodrigues DN, Rescigno P, Tunariu N, Liu XQ, Cristescu R, Schloss C, Yap C, de Bono JS. Eur Urol Oncol 5: 2022 659-667	23
NSD2 targeting reverses plasticity and drug resistance in prostate cancer. Li JJ, Vasciaveo A, Karagiannis D, Sun Z, Gretarsson KH, Chen X, Ouerfelli O, Socciarelli F, Frankenstein Z, Dong H, Zou M, Yuan W, Yang G, Aizenman GM, Pannellini T, Xu X, Beltran H, Chen Y, Gardner K, Robinson BD, de Bono J, Gozani O, Abate-Shen C, Rubin MA, Loda M, Sawyers CL, Califano A, Lu C, Shen MM. Nature 649: 2026 216-226	0

Publications

Citations

Immune Biomarkers in Metastatic Castration-resistant Prostate Cancer.
Fenor de la Maza MD, Chandran K, Rekowski J, Shui IM, Gurel B, Cross E, Carreira S, Yuan W, Westaby D, Miranda S, Ferreira A, Seed G, Crespo M, Figueiredo I, Bertan C, Gil V, Riisnaes R, Sharp A, Rodrigues DN, Rescigno P, Tunariu N, Liu XQ, Cristescu R, Schloss C, Yap C, de Bono JS. Eur Urol Oncol 5: 2022 659-667

NSD2 targeting reverses plasticity and drug resistance in prostate cancer.
Li JJ, Vasciaveo A, Karagiannis D, Sun Z, Gretarsson KH, Chen X, Ouerfelli O, Socciarelli F, Frankenstein Z, Dong H, Zou M, Yuan W, Yang G, Aizenman GM, Pannellini T, Xu X, Beltran H, Chen Y, Gardner K, Robinson BD, de Bono J, Gozani O, Abate-Shen C, Rubin MA, Loda M, Sawyers CL, Califano A, Lu C, Shen MM. Nature 649: 2026 216-226